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Abstract
Understanding the direction of information flow is essential for characterizing how genetic 
networks affect phenotypes. However, methods to find genetic interactions largely fail to reveal 
directional dependencies. We combine two orthogonal Cas9 proteins from Streptococcus pyogenes 
and Staphylococcus aureus to carry out a dual screen in which one gene is activated while a 
second gene is deleted in the same cell. We analyse the quantitative effects of activation and 
knockout to calculate genetic interaction and directionality scores for each gene pair. Based on the 
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results from over 100,000 perturbed gene pairs, we reconstruct a directional dependency network 
for human K562 leukemia cells and demonstrate how our approach allows the determination of 
directionality in activating genetic interactions. Our interaction network connects previously 
uncharacterised genes to well-studied pathways and identifies targets relevant for therapeutic 
intervention.
Genetic interaction mapping approaches compare single gene loss-of-function phenotypes 
against combinations of loss-of-function to identify aggravating or alleviating interactions1. 
However, studies to address the directionality of genetic interactions have been largely 
limited to lower eukaryotes2–6, despite the fact that elucidating human pathway 
directionality is key to properly interpreting functional genetic dependencies. Such basic 
information offers rational approaches for therapeutic intervention, precision medicine, and 
evading drug resistance in human cancers. At the most fundamental level, knowing the 
directional flow of genetic information is critical to properly reconstruct networks and 
assemble a cohesive picture of gene function.
The recently discovered bacterial CRISPR phage-defence system has remarkably advanced 
RNA interference and related gene perturbation technologies7. A growing CRISPR toolbox 
offers a diversity of approaches to perform a highly parallel functional interrogation of every 
single gene in the human genome8,9. However, whereas single perturbation (e.g. knockout or 
overexpression) approaches have proven highly successful to systematically attribute 
function to individual mammalian genes, they typically do not provide a deeper 
understanding of how these genes function together in complex genetic signalling networks.
To reconstruct directional regulatory networks in human cells, we developed an orthogonal 
CRISPR system comprising two Cas9 enzymes derived from different species. This system 
allows the simultaneous and asymmetric activation of one gene and deletion of a second 
gene in the same cell. When compared to conventional symmetrical loss-of-function 
experiments in which the function of both interaction partners is lost, our orthogonal 
asymmetric platform allowed us to determine whether the activated gene functionally 
depends on, or can compensate for the loss of a deleted gene. Using this platform, we 
identified directional genetic interactions between genes whose activation or ablation altered 
the fitness of human chronic myeloid leukaemia (CML) cells. We demonstrate that the 
orthogonal screening approach can quantify loss- and gain-of-function phenotypes from the 
same cell, and that it is suitable to systematically identify genetic interactions between 
cancer relevant genes. We reconstruct a substantial number of directional dependencies, 
connecting previously uncharacterised genes to well-studied pathways.
Results
CRISPRa screen identifies cancer pathway genes
CML is a leukaemia characterised by a reciprocal translocation between chromosome 9 and 
22. This translocation creates the BCR-ABL fusion oncogene, a constitutively active 
tyrosine kinase oncogene that causes myeloid precursor cells to divide in an uncontrolled 
fashion10. Application of BCR-ABL tyrosine kinase inhibitors (e.g. imatinib) have 
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revolutionised treatment for this cancer, and decades of study have yielded fundamental 
information on the genes critical for BCR-ABL dependent signalling. We thus chose CML 
to benchmark our method to identify directional genetic interactions, using the K562 CML 
cell line to systematically quantify genes that function as negative or positive regulators of 
cancer cell fitness.
To ascertain CRISPR screening conditions capable of identifying the full gamut of imatinib 
dependent phenotypes, we characterised K562 cell response to a broad range of imatinib 
drug concentrations. We found that K562 cells respond to a wide range of imatinib 
concentrations (10 – 1,000 nM), and that CRISPR mediated activation (CRISPRa) of the 
imatinib efflux transporter ABCB1 using the SunTag system11 can result in an 
approximately 2-fold increase in the IC50 after 3 days of treatment (Supplemental Fig. 1a). 
However 3 days of drug treatment did not provide the dynamic range needed to identify 
genes displaying weaker phenotypes in a screen. To optimise conditions, we analysed the 
influence of repeated imatinib treatment cycles at IC50 on cell viability. We observed 
increased cell viability for ABCB1 overexpressing cells, 31.5-fold (sgABCB1-1) and 23.5-
fold (sgABCB1-2) over negative controls (sgNTC), after three cycles of 100 nM imatinib 
(day 9) (Supplemental Fig. 1b). These results show that repeated exposure to low imatinib 
doses allows for much greater enrichment of cells with activated resistance genes than a 
single treatment.
To systematically identify genes whose activation can alter imatinib drug response, we 
created an ultra-complex, genome-scale sgRNA library consisting of over 260,000 total 
sgRNAs targeting every coding and over 4,000 non-coding Refseq annotated (hg19) 
transcripts in the human genome. Quality-controlled sgRNA libraries (Supplemental Fig. 2) 
were introduced into K562 CRISPRa target cells11 followed by 14 days of imatinib 
treatment with escalating doses of imatinib ranging from 100 nM (IC50) to 300 nM (IC80) 
(Fig. 1a). Abundance of sgRNA encoding sequences was determined via next generation 
sequencing (NGS), comparing the beginning (baseline) and endpoint (day 14) of the screen 
(Supplemental Table 1). NGS read count ratios of the top 25% most enriched/disenriched 
sgRNAs were normalized to define an enrichment score (τ) for each gene (Supplemental 
Table 2). Activation phenotypes were found to be highly reproducible (r>0.98) between 
technical screen replicates (Supplemental Fig. 3). From a total of 26,700 targeted transcripts, 
we observed that the activation of 332 genes significantly (FDR<0.05, p<0.001) altered the 
fitness of imatinib treated K562 cells, with 57% (188 genes) causing significant depletion 
(blue) and 43% (144 genes) driving cell enrichment (Fig. 1b).
A key advantage of the gain-of-function approach used here, as opposed to more commonly 
employed loss-of-function approaches, is that genes exhibiting no- to very low-expression 
can also be investigated. We found that out of the 332 candidate genes, 21% were not 
expressed in K562 cells (FPKM<100) indicating that imatinib responsive genes could be 
identified from the full spectrum of endogenous gene expression levels (Supplemental Table 
2 and Supplemental Fig. 4). This approach allows for the study of genes which may have 
functional relevance in other cell types, i.e. different types of cancers including non-CML 
leukemias.
Boettcher et al. Page 3
Nat Biotechnol. Author manuscript; available in PMC 2018 August 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
To assess the quality of the screening data on a global level, we executed a gene set 
enrichment analysis (GSEA)12,13 using the above 332 target genes identified in the imatinib 
CRISPRa screen. GSEA identified the strongest gene enrichment in leukaemia and other 
cancer-related KEGG signalling pathways (Supplemental Fig. 5a), illustrating the ability to 
identify positive and negative regulators of cancer cell survival pathways. A graphic 
summary of the CRISPRa screen results, assembled into their relevant oncogenic pathways 
is shown in Supplemental Fig. 5b. The three strongest hits, namely ABCB1, ABCG2 and 
BCR-ABL are well known to be overexpressed in CML patients with high tolerance to 
imatinib14. Additionally, we identified BCR-ABL binding partners CBL and CRKL 15, and 
downstream effectors SOS1, SOS2, GAB2, RAF1, MYC, PIM1, PIM2 and STAT5B 16, the 
c-Abl phosphatase PTPN12 17, the Ras-GAPs NF1, RASA1 and RASA3 18, the cell cycle 
regulators CDK6 19 and CCND3 20 and receptor tyrosine kinases having well documented 
roles in imatinib resistance, specifically PDGFRB 21, FGF1R 22, CSF1R 23 and AXL 24.
To evaluate the reproducibility of the CRISPRa screen data, we tested three sgRNAs per 
gene, against 20 of the 332 significant candidate genes individually in an arrayed 96 well 
plate validation assay. Genes selected for validation included the five most significantly 
enriched candidate genes BCR-ABL, ABCB1, SLC6A14, CDK6 and MYC as well as 15 
genes whose activation produced less significant phenotypes (Supplemental Table 3). The 
sgRNAs targeting these 20 genes were selected based on CRISPRa screen enrichment 
(Supplemental Table 1). The results showed a high degree of quantitative reproducibility 
when compared to screen enrichment data (r=0.78), displaying a wide dynamic enrichment 
range over several orders of magnitude (Supplemental Fig. 6). In addition to the large 
number of aforementioned genes with well-established roles in leukaemia and imatinib 
resistance, we identified and validated a set of candidate genes with uncharacterised roles in 
cancer therapy resistance (Fig. 1c), including numerous solute carriers, the non-coding 
RNAs PVT1 and LOC101928865, as well as BBX, NOL4L and ZC3HAV1 for which 
upregulation following sgRNA expression was further confirmed via qRT-PCR 
(Supplemental Fig. 7). In total, these experiments yielded a highly reproducible list of target 
genes, some having well-established functions in cancer pathways, while others are 
completely uncharacterised. These results gave us the opportunity to study the functional 
relationships between the genes; hence, we sought to develop an orthogonal CRISPR 
platform that could illuminate genetic interactions and directional dependencies for drug 
resistance.
The orthogonal CRISPR system
To enable the scalable investigation of directional dependencies, we conceptualized an 
orthogonal CRISPR system that would allow the simultaneous activation and deletion of two 
genes in the same cell. To test this concept, we developed a K562 cell line harbouring the 
Streptococcus pyogenes based SunTag CRISPRa system and Cas9 nuclease from 
Staphylococcus aureus (SaCas9). These two Cas9 proteins have different PAM requirements 
and structural studies have shown that each enzyme recognises different constant regions of 
the cognate sgRNA25,26. These observations suggest that each Cas9 enzyme is not likely to 
cross-react with the cognate sgRNA engineered for the other Cas9 enzyme.
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To test whether both CRISPR systems can work in parallel to activate and delete genes in the 
same cell without cross-interference, we designed orthogonal sgRNA expression constructs 
to activate the imatinib efflux transporter ABCG2 in combination with a non-target control 
sgRNA, or alternatively, in combination with an sgRNA that deletes ABCG2 (Fig. 2a). As 
expected, ABCG2 protein levels increased following the expression of a CRISPRa sgRNA 
against ABCG2 (Fig. 2b, left panel). In contrast, ABCG2 expression is almost completely 
abolished when the same CRISPRa sgRNA is used in combination with an sgRNA that 
deletes ABCG2 via SaCas9 nuclease (Fig. 2b, right panel). A small residual population of 
ABCG2 expressing cells can be observed, which we suspect likely represents cells 
harbouring non-edited or in-frame indels of the ABCG2 gene (Fig. 2b, right panel). To 
compare drug resistance profiles of these sgRNA constructs, we analysed cell enrichment 
following 11 days of imatinib treatment (Fig. 2c). As shown in Figure 1c, ABCG2 activation 
confers imatinib resistance; however, resistance is almost completely reversed in cells that 
concomitantly express an sgRNA that deletes ABCG2 (Fig. 2c). Taken together, these data 
demonstrate the ability of the orthogonal CRISPR platform to simultaneously functionally 
activate and delete genes in the same cell.
Since our orthogonal system is based on two completely independent CRISPR systems, it 
opens the door to combinations of any two CRISPR-based technologies, such as 
transcriptional silencing27 or targeted DNA methylation28, which represents a substantial 
advance compared to the only other orthogonal CRISPR-based method published to date by 
Dahlman et al.29, which achieves gene activation and knockout using ‘catalytically dead’ 
sgRNAs engineered to bind the MS2:P65:HSF1 (MPH) activation complex in combination 
with a catalytically active wt CRISPR Cas9 nuclease from S.pyogenes. In contrast, our 
approach is based on Cas enzymes from two different bacterial species – S.pyogenes and 
S.aureus – both of which recognize distinct sgRNAs and PAMs. Consequently, the co-
expressed sgRNAs for either CRISPR system do not compete for common protein factors or 
target sites within the same cell.
Systematic quantification of genetic interactions
To establish a high-throughput screen using the above described orthogonal CRISPR 
platform, we created an orthogonal dual sgRNA library composed of selected combinations 
of CRISPRa and SaCas9 nuclease sgRNAs. This library combined activating sgRNAs 
targeting 87 enriched or depleted candidate genes from the primary screen (2 sgRNAs/gene 
for a total of 174 sgRNAs) and knockout sgRNAs targeting 1,327 genes (8 sgRNAs/gene for 
a total of 11,594 sgRNAs). The knockout sgRNA population targeted all KEGG annotated 
cancer-relevant signalling pathway genes. The final dual orthogonal sgRNA library 
contained a total of over 2 million sgRNA or 100,000 gene combinations (annotated library 
sequences are provided in Supplemental Tables 4 and 5) targeting well-established and dark 
matter genes.
To promote rigour and reproducibility, the complex sgRNA combination expression library 
was transduced into two independently derived clonal lines of orthogonal K562 cells. The 
clonal lines were screened in parallel, in two separate bioreactors in the presence of 
escalating doses of imatinib. After 19 days, cells from both bioreactors were harvested and 
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sgRNA representation was compared between baseline cells (day 0) and imatinib-treated 
cells (day 19, see Methods for details). Before calculating genetic interactions, it was 
imperative that we first calculated the effects of single gene activation-only and knockout-
only phenotypes. To facilitate this calculation, we included a large number of non-target 
control sequences in the combination library; 18 non-target controls in the CRISPRa 
position and nearly 900 in the SaCas9 nuclease position (see Supplemental Tables 4 and 5). 
Dissecting these two populations of control vectors allowed the clean evaluation of replicate 
performance for both single gene activation (r=0.96, Fig. 3b) and single gene knockout 
phenotypes (r=0.98, Fig. 3c). Both single gene activation and single gene knockout 
phenotypes included negative and positive regulators of cell fitness in the presence of 
imatinib. These results were highly reproducible between replicates (Fig. 3b and c), and 
CRISPRa values correlated (r=0.9267) with values from the initial CRISPRa screen 
(Supplemental Fig. 8).
Notably, phenotypic measurements derived from all possible combinations of sgRNAs in the 
activation and knockout position with one another were also found to be highly reproducible 
between clonal screen replicates (r=0.94), allowing a quantitative comparison of all possible 
combinations of sgRNAs in their full operationally functional orthogonal context (Fig. 3d). 
Taken together these data confirm: 1) the ability for both Cas9 systems to work in parallel to 
produce activation and knockout phenotypes in the same cell, and 2) the suitability of our 
NGS analysis pipeline to accurately quantify phenotypes from combinatorial gene 
perturbations.
Deducing directional dependencies
In genetic interactions where a gene activates its partner, gene activation and knockout 
produce opposing phenotypes (τact and τko) and the double perturbation phenotype (τact+ko) 
can lie in the full spectrum between both individual perturbation phenotypes (Fig. 3e). To 
systematically identify and quantitate directional genetic dependencies from the screen, we 
determined genetic interaction (GI) scores from individual and combinatorial τ values and 
based on those, defined a single directionality score Ψ (Fig. 3f). In essence, Ψ displays a 
negative value when enrichment scores τ from gene activation and knockout have opposing 
signs, as would be expected in activating interactions. For interactions with negative Ψ 
scores, the τact and GI scores were multiplied to determine whether the activated gene 
functions downstream (positive value) or upstream (negative value) of the deleted gene (Fig. 
3g).
To maintain rigor, we assigned directionality only in reproducible genetic interactions (GI 
scores that exceeded a 1x standard deviation in both clonal cell line replicates) that exhibited 
a negative Ψ score. A summary of all calculated τ, GI and Ψ values is shown in 
Supplemental Table 6. Based on the determined GI and Ψ scores, we derived a directional 
genetic interaction network de novo. We assembled the network from the most significant 
and reproducible directional and non-directional interactions determined by the orthogonal 
screen (Fig. 3h; Supplemental Table 7 and Supplemental Figure 9). As explained above, 
directionality among genetic interactions can be inferred only when the activated gene 
displayed the opposite phenotype of the knocked-out gene; but not if activation and 
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knockout both resulted in the same phenotype (Supplemental Fig.10). The resulting 
directional-edge model connects a total of 70 cancer-centric nodes, via 137 gene:gene 
interactions determined from both clonal replicates, for 26 of which directionality could be 
directly inferred. For clarity, interactions for all 70 individual nodes are depicted in 
Supplemental Figure 11.
To quantitatively evaluate the orthogonal screen data, we validated the performance and 
calculated pathway directionalities in several independent assays. First, a sample set of 
predicted directional interactions between selected genes with negative Ψ scores which 
passed the cut-off in clonal replicate 2 (Supplemental Table 6) were re-tested in an arrayed 
validation assay using the same orthogonal clonal line. Single as well as combinatorial 
activation and knockout τ values from the arrayed validation experiments were determined 
and used to derive GIv and Ψv scores (Fig. 4a). Control single gene activation and knockout 
phenotypes validated for all re-tested genes. Activation of SPRED2, WT1 and TFAP2A had 
a sensitizing effect to imatinib treatment, while deletion of PTPN1, NF1, MAP4K5 and 
RASA2 caused cells to steadily enrich in the culture over time (Fig. 4b and Supplemental 
Table 8). Figure 4b shows single and double perturbation τ values of twelve gene:gene 
combinations, determined on day 14 of the arrayed validation along with calculated GIv and 
Ψv scores.
Overall, GIv scores were found to be in good agreement (r=0.72) with GI scores determined 
by the orthogonal screen (Supplemental Table 9). In five cases the activated gene was unable 
to execute its sensitizing function following the deletion of its interaction partner (τact x GI = 
negative: SPRED2-NF1, WT1-PTPN1 and TFAP2A-PTPN1/-NF1/-MAP4K5), supporting a 
model for an upstream function of the activated gene. In contrast, we observed three 
instances where the activated gene could compensate for the loss of its interaction partner 
(τact x GI = positive: SPRED2-PTPN1/-RASA2 and WT1-MAP4K5), supporting a model 
for a downstream function of the activated gene. Out of the total of twelve tested 
combinations, ten were predicted by the orthogonal screen to show a directional interaction, 
of which the aforementioned eight were confirmed by our arrayed validation while two 
interactions (WT1-NF1 and TFAP2A-RASA2) did not reproduce (Fig. 4b and Supplemental 
Table 9). The inability to validate those two interactions might be explained by the markedly 
different experimental conditions between the orthogonal screen in a 14 L agitated 
bioreactor with precisely controlled culture conditions versus validation in a 96-well plate. 
Moreover, GI and Ψ scores from the screen were calculated based on multiple sgRNAs for 
gene activation and knockout whereas validation was performed with one selected sgRNA in 
either position.
Based on the validated interactions, we reconstructed a Ras-centric high-confidence 
directional genetic interaction model with Ψv scores calculated from the validation data 
(Fig. 4c). This model is further supported by our findings that SPRED2 cannot sensitise 
NF1-deleted cells to imatinib treatment, despite showing a similar increase in mRNA levels 
following its activation (Supplemental Fig. 12a and b). At this point it is important to 
mention that the relative changes in gene expression, as detected by qRT-PCR, do not 
necessarily translate into equivalent phenotypes. In other words, although the significant 
increase in SPRED2 mRNA levels following its CRISPRa mediated activation might seem 
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modest (approx. 2 fold), the detected phenotype at 8 days after imatinib treatment is a 
remarkably significant 3-fold decrease in cell numbers (Supplemental Data Figure 12). 
Moreover, SPRED2 overexpression in HEK293T cells lowered Ras-GTP levels only in the 
presence of NF1, confirming that the ability of SPRED2 to suppress Ras activity depends on 
NF1 (Supplemental Figure 12c). These observations build upon previous observations that 
double knockdown of SPRED1/2 leads to increased Ras-GTP levels due to disruption of an 
NF1/SPRED2 complex30.
Exploiting genetic vulnerabilities for cancer therapy
Given the potential to discover genetic dependencies of therapeutic relevance, we 
investigated the observed interaction between NF1 and the TAM receptor tyrosine kinase 
AXL31 (Fig. 3h and Supplemental Table 7). Targeting AXL-mediated signaling pathways 
can lead to regained drug sensitivity and improved therapeutic efficacy, defining AXL as a 
promising target for cancer therapeutics32,33. However, a key issue for therapeutic 
intervention is the selection of appropriate biomarkers and potential synergistic drug targets 
for combination-based regimes. To evaluate therapeutic applicability and potential synergies, 
we applied R428 (a specific AXL inhibitor which is currently being evaluated in clinical 
trials34) to a population of Cas9 NF1-knockout sgRNA treated cells as well as control cells. 
We found that NF1-knockout cells were highly sensitive to R428, whereas NF1-wildtype 
control cells did not show a significant response to 8 days of treatment with 500 nM R428 
(Fig. 5a). Given that the NF1-knockout sgRNA treated cells contain sub-populations of non- 
and in-frame edited cells (Supplemental Fig.13) we anticipate that these observations likely 
underestimate R428 drug sensitivity. Moreover, these observations were also extended to 
lung epithelial cells using RNAi mediated knockdown of NF1 in BEAS-2B cells, which 
displayed significantly increased drug sensitivity (p=3x10−3 at 500 nM R428, p=6x10−5 at 
1000 nM R428) when compared to matched control cells (Supplemental Fig. 14). Finally, 
we confirmed that NF1-knockout K562 cells are more resistant to treatment with imatinib, 
but that these cells can be re-sensitised to imatinib by R428 treatment (Fig. 5b).
To explore the nature of the selective AXL dependency of NF1-deficient cells, we 
quantitated phosphorylated AXL kinase (p-AXL) levels in control untreated wildtype cells 
and NF1-knockout sgRNA treated cells. NF1-knockout sgRNA cells displayed markedly 
higher levels of p-AXL than NF1-wildtype cells, indicating that these cells had accumulated 
higher levels of AXL activity and p-AXL levels were reduced upon R428 treatment in both, 
NF1-wildtype and knockout cells (Fig. 5c). To further investigate the interaction between 
NF1 and AXL, we performed a homogeneous time-resolved Förster resonance energy 
transfer (TR-FRET) assay where the stringent proximity (<10 nm) based idiosyncrasy 
allows the detection of direct physical interactions35. These experiments provided additional 
support that NF1 and AXL physically interact with each other in a cell based assay (Fig. 5d). 
Additionally, we show that both proteins bind to all three Ras isoforms N-Ras, H-Ras and K-
Ras (Supplemental Figure 15), supporting a model where NF1 deficient cells become 
increasingly dependent on AXL signalling, and that these cells can be selectively targeted by 
the AXL inhibitor R428. Given the high recurrence of NF1 mutations and AXL activation in 
a variety of human cancers, our data provide an informed basis for therapeutic intervention.
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Discussion
Inferring the direction of genetic interactions has been a long-standing challenge. While 
previously described genetic interaction studies are based on simple dual loss-of-
function36–39,40–43, the orthogonal approach combines the power of CRISPR mediated 
activation of one interaction partner with the functional loss of a second gene in the same 
cell. Here we establish the full methodology and reagents necessary to conduct highly 
parallel directional CRISPR screens in human cancer cells, including stable CRISPRa-
SaCas9 nuclease cell lines, dual sgRNA libraries, and a barcode-free next generation 
sequencing strategy to quantify sgRNA combinations in orthogonal screens. As a general 
concept, our described inference of directionality strategy is readily applicable to numerous 
other dual activation/inhibition expression embodiments, notwithstanding other 
transcriptional, post-transcriptional, and post-translational regulatory modules.
Approaches to construct quantifiable directional models for genetic interactions have been 
limited and there have been no established technologies to efficiently specify directionality 
within pathways. This is particularly a problem in fields such as cancer biology where a 
major ongoing focus is to identify synergistic genetic vulnerabilities that provide a sound 
basis for the design of rational polytherapies to help prevent drug resistance. Here, we 
provide a comprehensive dataset consisting of single and combinatorial gain- and loss-of-
function phenotypes in CML cells, and a high-confidence network of genetic interactions 
that will help researchers to build hypotheses to further understand why some patients 
respond well to tyrosine kinase inhibitors like imatinib, whereas others acquire resistance. In 
many cases, directional dependencies need to be considered when designing a treatment plan 
for patients harbouring multiple genetic lesions, and the described orthogonal platform 
offers a fresh new approach to uncovering key dependencies in pathways critical for human 
gene function and disease.
Methods
Vector maps
For the single sgRNA (sgLenti), dual sgRNA (sgLenti-orthogonal) and SaCas9 nuclease 
vector, vector maps are provided in Genbank format (Supplemental 1–3) and have been 
deposited along with the plasmids at Addgene
CRISPRa and orthogonal K562 cell lines
K562 CRISPRa cells11,46 were kindly provided by Luke Gilbert and cultured in RPMI 1640 
medium, supplemented with 10% fetal bovine serum and 1x Anti-Anti (Gibco). Via 
lentiviral transduction, S. aureus Cas9 under the control of an EF1α promoter, was 
introduced into K562 CRISPRa cells (see Supplemental 3 for vector map). Successfully 
transduced cells were selected with hygromycin (200 ug/mL) and single clones were 
expanded for 14 days. To test functionality of the expanded clonal orthogonal lines, cells 
were transduced with sgRNAs to activate the imatinib efflux transporter ABCG2 via 
CRISPRa (5′-GCCACTGCGTTCAGCTCTGG-3′) or to knock it out in combination with 
SaCas9 (5′-CATCTGCTATCGAGTAAAACTG -3′). Four weeks post introduction of the 
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SaCas9 expression cassette, clonal lines were screened for functionality of both CRISPR 
systems (CRISPRa and SaCas9 nuclease) via flow cytometry analysis of >10,000 cells 
stained with CD338 (ABCG2) antibodies (Miltenyi, 130-104-960). Out of a total of 28 
screened orthogonal lines, all 28 retained the functional CRISPRa system but only four lines 
displayed stable function of SaCas9 nuclease. Two of those lines were used for the 
orthogonal CRISPR screen.
CRISPRa and orthogonal sgRNA library design
For the initial CRISPRa screen, a genome-scale sgRNA library consisting of over 260,000 
total sgRNAs targeting every coding, and over 4,000 non-coding, Refseq annotated (hg19) 
transcripts in the human genome, as well as every unique protein coding isoform with up to 
12 sgRNAs, plus 7,700 non-target control sequences (NTC).
The promoter regions for coding transcripts targeted windows 25 to 500bp upstream of the 
Refseq-annotated transcription start sites. SgRNAs were designed against targets in the 
promoters that are of the format (N)20NGG, and selected sgRNAs must pass the following 
off-targeting criteria: 1) the 11bp-seed must not have an exact match in any other promoter 
region, and 2) if there is an exact off-target seed match, then the rest of the sgRNA must 
have at least 7 mismatches with the potential off-target site. Regions outside a window of 25 
to 500 bp upstream of the TSS were not considered for off-targeting since the employed 
CRISPRa system was shown to work only in proximity to the TSS of genes46 and to not 
further limit the number of designable sgRNAs for the narrow on-target space. After all 
sgRNAs that pass off-targeting criteria were generated, up to 12 sgRNAs/transcript were 
selected that were nearest to the transcription start sites. All sgRNA sequences are shown in 
Supplemental Table 1. In addition to the sgRNA sequence, every plasmid contained a unique 
20 nt barcode sequence (see Supplemental 1 for vector map). This sequence allowed the 
distinction between sgRNAs expressed from different plasmids and hence in different sub-
populations of cells and was used to bin cells into mutually exclusive barcode bins to create 
technical screen replicates after sequencing.
For the orthogonal genetic interaction screen, a focused nuclease-active S. aureus Cas9 
library was generated targeting 1327 genes. For the selected genes, sgRNAs targeting coding 
exons were generated using Cas-Designer 47, generating sgRNAs that were adjacent to the 
PAM sequence ‘NHGRRT’ (H = A, C, or T), which allows for targeting with S. aureus Cas9 
but not with S. pyogenes Cas9. Potential off-targets against the human genome were 
identified using Cas-OFFinder48. To score sgRNA sequences by Cas-OFFinder, sgRNAs that 
have perfect-seed off-targets and 5 mismatches or less in potential off-target regions were 
penalised. The 20% of sgRNAs with the highest off-target penalties and bottom 20% of 
sgRNAs with the lowest out-of-frame scores from Cas-Designer were eliminated. From the 
resulting list of sgRNAs, up to 8 sgRNAs/gene were selected, targeting the most 5′ 
constitutive exons for each gene.
CRISPRa and orthogonal sgRNA library cloning
For the CRISPRa library, the designed 20 nt target specific sgRNA sequences were 
synthesised as a pool, on microarray surfaces (CustomArray, Inc.), flanked by overhangs 
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compatible with Gibson Assembly49 into the pSico based sgLenti sgRNA library vector (see 
Supplemental 1 for vector map). The synthesised sgRNA template sequences were of the 
format: 5′-GGAGAACCACCTTGTTGG-(N)20-GTTTAAGAGCTATGCTGGAAAC-3′. 
Template pools were PCR amplified using Phusion Flash High-Fidelity PCR Master Mix 
(ThermoFisher Scientific) according to the manufacturers protocol with 1 ng/uL sgRNA 
template DNA, 1 uM forward primer (5′-GGAGAACCACCTTGTTGG-3′), 1 uM reverse 
primer (5′-GTTTCCAGCATAGCTCTTAAAC-3′) and the following cycle numbers: 1x 
(98C for 3 min), 15x (98C for 1 sec, 55C for 15 sec, 72C for 20 sec) and 1x (72C for 5 min). 
PCR products were purified using Minelute columns (Qiagen). The library vector sgLenti 
was preapred by restriction digest with AarI (Thermo-Fischer) at 37C overnight, followed by 
1% agarose gel excision of the digested band and purification via NucleoSpin columns 
(Macherey-Nagel). Using Gibson Assmbly Master Mix (NEB), 1000 ng digested sgLenti 
and 100 ng amplified sgRNA library insert were assembled in a total 200 uL reaction 
volume. The reaction was purified using P-30 buffer exchange columns (Biorad) that were 
equilibrated 5x with H2O and the total eluted volume was transformed into three vials of 
Electromax DH5α (ThermoFisher). E.coli were recovered, cultured overnight in 500 mL LB 
(100 ug/mL ampicillin) and used for Maxiprep (Qiagen). In parallel, a fraction of the 
transformation reaction was plated and used to determine the total number of transformed 
clones. The coverage was determined to be 70x clones per sgRNA ensuring even 
representation of all library sgRNA sequences and their narrow distribution (Supplemental 
Fig. 2). Fidelity of sgRNA sequences was confirmed with a more than 90% perfect Bowtie 
alignment rate and narrow distribution of sgRNA sequences, with read counts for 87% of 
sgRNA sequences falling within a single order of magnitude.
For orthogonal CRISPR libraries, CRISPRa sgRNA pools of 174 sgRNA against 87 selected 
target genes (2 sgRNAs/gene) plus 18 non-target control sgRNAs were cloned into position 
1 of the AarI-digested plasmid sgLenti-orthogonal exactly as described for the CRISPRa 
library. Off target analysis using Cas-OFF finder48 showed that out of the total 192 sgRNAs, 
only two had an additional perfectly matched genomic target site which was outside of the 
defined relevant CRISPRa off-target space (25 to 500 nt upstream of the TSS) while the rest 
had exactly one target site. In addition, 6 sgRNAs had off-target sites with 1 mis-match and 
65 sgRNAs had off-target sites with 2 mis-matches outside the defined off-target space. A 
full summary of CRISPRa sgRNA sequences with the number and nature of determined off-
target sites is shown in Supplemental Table 4.
Following amplification in E.coli, library plasmids with the first position cloned were 
digested with BfuAI (NEB) to allow cloning of SaCas9 sgRNAs into the second position. To 
remove undigested orthogonal sgRNA library plasmid from the pool, the purified 
(Nucleospin, Macherey-Nagel) BfuAI digested plasmid was subsequently digested with 
AscI for which restriction sites exist in the stuffer sequences in both sgRNA positions 1 and 
2. BfuAI/AscI digested plasmid was extracted from 1% Agarose gel (Nucleospin, Macherey-
Nagel).
Synthesised SaCas9 sgRNA template sequences (12,500 total, 8 sgRNAs/gene) were of the 
format: 5′-GAAAGGACGAAACACCGTG-(N)22-
GTTTTAGTACTCTGGAAACAGAATCT-3′. PCR amplification of the SaCas9 template 
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pool was performed as described above using primer sequences: 5′-
GAAAGGACGAAACACCGTG-3′ and 5′-AGATTCTGTTTCCAGAGTACTAAAAC-3′ 
and the purified PCR product was cloned into BfuAI digested sgLenti-orthogonal (see 
Supplemental 2 for vector map) via Gibson Assembly as described above. The resulting 
orthogonal sgRNA library was transformed into Electromax cells at 30x coverage as 
described above and the plasmid sgRNA library pool was purified (Qiagen Plasmid Maxi 
kit). From the resulting plasmid pool, sgRNA sequences were recovered via PCR as 
described below and sequenced for quality control. At a read depth of 94x, 2.389 million out 
of the total possible 2.394 million combinations (>99%) were read at least once, with less 
than 5% of the library elements read 20 or less times.
Lentivirus production
HEK293T cells were seeded at 65,000 cells per ccm in 15 cm dishes in 20 mL media 
(DMEM, 10% fetal bovine serum) and incubated overnight at 37C, 5% CO2. The next 
morning, 8 ug sgRNA library plasmid, 4 ug psPAX2 (Addgene #12260), 4 ug pMD2.G 
(Addgene #12259) and 40 uL jetPRIME (Polyplus) were mixed into 1 mL serum free 
OptiMEM (Gibco) with 1x jetPRIME buffer, vortexed and incubated for 10 min at RT and 
added to the cells. 24 h later, 40U DNAseI (NEB) were added to each plate in order to 
remove untransfected plasmid and at 72h post-transfection, supernatant was harvested, 
passed through 0.45 um filters (Millipore, Stericup) and aliquots were stored at −80C.
Genome-wide and orthogonal CRISPR screens
Imatinib selection conditions for all screens were optimized by activating the imatinib efflux 
transporter ABCB1 using sgABCB1-1 (5′-CAGGAACAGCGCCGGGGCGT-3′) and 
sgABCB1-2 (5′-AGCATTCAGTCAATCCGGGC-3′) (Supplemental Figure 1). K562 
CRISPRa/orthogonal cells were transduced with lentivirally packaged sgRNA libraries at 
MOI=0.3 and 500x coverage. The low MOI was used to reduce the frequency of multiple-
infected cells; thus, only one gene was activated in each cell. Cells were then cultured in 
RPMI with 10% FBS and 1x Anti-Anti (Gibco) in a 37C incubator with 5%CO2. 48h post 
transduction, cells were selected with puromycin (2 ug/mL) for 96h. Following selection, 
aliquots of 300 million cells each, were frozen down in FBS with 10% DMSO for later 
analysis via NGS (see below). Fully selected cells (300 million) were transferred into a 14 
liter CelligenBlu bioreactor (Eppendorf) and sub-cultured at 37C, pH=7.4 and 2% oxygen. 
Coverage at cell level was kept above 1000x throughout the entire screen and the culture was 
diluted with fresh medium when cell density reached 1 mio/mL.
For the genome-wide CRISPRa screen: 14 days post transduction, aliquots of 300 mio cells 
from the beginning of the screen were frozen down (baseline sample) as described above and 
an IC50 concentration of 100 nM imatinib (Sigma) was added to the bioreactor vessel. 
Imatinib was refreshed on day 17 (IC60 = 150 nM) and day 19 (IC80 = 300 nM) after initial 
sgRNA library transduction and cells for the analysis of the final time point were harvested 
on day 28. For the orthogonal genetic interaction screen: Puromycin selected cells (2 ug/mL) 
at 8 days post transduction (2.5 billion per sample) were frozen down as described above 
and 100 nM imatinib (IC50) were added to the bioreactor vessel. Imatinib concentrations 
were increased throughout the screen to the IC60 concentration of 150 nM (day 10), the IC80 
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of 300 nM (day 13 and 15) and finally the IC90 of 500 nM (day 17). On day 19 2.5 billion 
cells per sample were harvested for downstream analysis via NGS as described below.
Genomic DNA (gDNA) extraction
Cell pellets from baseline and imatinib treated samples were resuspended in 20 mL P1 
buffer (Qiagen) with 100 ug/mL RNase A and 0.5% SDS followed by incubation at 37C for 
30 min. After that, Proteinase K was added (100 ug/mL final) followed by incubation at 55C 
for 30 min. After digest, samples were homogenised by passing them three times through a 
18G needle followed by three times through a 22G needle. Homogenised samples were 
mixed with 20 mL Phenol:Chlorophorm:Isoamyl Alcohol (Invitrogen #15593-031), 
transferred into 50 mL MaXtract tubes (Qiagen) and thoroughly mixed. Samples were then 
centrifuged at 1,500g for 5 min at room temperature (RT). The aqueous phase was 
transferred into ultracentrifuge tubes and thoroughly mixed with 2 mL 3M sodium acetate 
plus 16 mL isopropanol at RT before centrifugation at 15,000g for 15 min. The gDNA 
pellets were carefully washed with 10 mL 70% ethanol and dried at 37C. Dry pellets were 
resuspended in H2O and gDNA concentration was adjusted to 1 ug/uL. The degree of gDNA 
shearing was assessed on a 1% agarose gel and gDNA was sheared further by boiling at 95C 
until average size was between 10–20 kb.
PCR recovery of sgRNA sequences from gDNA
Multiple PCR reactions were prepared to allow amplification of the total harvested gDNA 
from a 1000x cell coverage for each sample. For the first round of two nested PCRs, the total 
volume was 100 uL containing 50 ug sheared gDNA, 0.3 uM forward (5′-
ggcttggatttctataacttcgtatagca-3) and reverse (5′-cggggactgtgggcgatgtg-3′) primer, 200 uM 
each dNTP, 1x Titanium Taq buffer and 1 uL Titanium Taq (Clontech). PCR cycles were: 1x 
(94C - 3 min), 16x (94C - 30 sec, 65C – 10 sec, 72C – 20 sec), 1x (68C – 2 min). All first 
round PCRs were pooled and a fraction was used as template for the second round PCR. The 
total volume of the second round PCR was 100 uL containing 2 uL pooled first round PCR, 
0.5 uM forward (5′-
AATGATACGGCGACCACCGAGATCCACAAAAGGAAACTCACCCTAAC-3′) and 
reverse (5′-CAAGCAGAAGACGGCATACGAGAT-(N)6-
GTGACTGGAGTTCAGACGTG-3′) primer where (N)6 is a 6 nt index for sequencing on 
the Illumina HiSeq platform, 200 uM each dNTP, 1x Titanium Taq buffer and 1 uL Titanium 
Taq (Clontech). PCR cycles were: 1x (94C - 3 min), 16x (94C - 30 sec, 55C – 10 sec, 72C – 
20 sec), 1x (68C – 2 min). The resulting PCR product (344 bp) was extracted from a 1% 
agarose gel. For the orthogonal genetic interaction screen, conditions for the first round PCR 
were slightly modified to: total reaction volume 80 uL containing 20 ug sheared gDNA and 
the second round PCR product was 887 bp.
Gel extracted bands from the primary CRISPRa screen were submitted for sequencing on an 
Illumina HiSeq 2500 platform using paired end 50 kits with the custom sequencing primer 
5′-GAGACTATAAGTATCCCTTGGAGAACCACCTTGTTGG-3′ for reading the sgRNA 
sequence and the Truseq Illumina reverse primer to read out 20 nt random barcode 
sequences used for generation of technical screen replicates (separation of sgRNA reads into 
three groups with mutually exclusive barcode sequence bins). For orthogonal dual sgRNA 
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library analysis, single end 50 kits were used and read cycles were split, 25 cycles for Read1 
with the sequencing primer above (reading the S.pyogenes sgRNA) and 25 read cycles for 
the ‘Illumina indexing read’ with the custom indexing primer 5′-
TTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGTG-3′ (reading the S.aureus 
sgRNA).
Data analysis
Total read counts of sgRNA sequences from each NGS sample were collapsed and 
quantified via alignment to the sgRNA library reference sequences using Bowtie 2.014. Data 
analysis was conducted similarly as described previously38,44. Briefly, for the primary 
CRISPRa screen, the frequency of sgRNAs was determined by deep sequencing and the 
average read count of three technical replicates was used. The phenotype τ was calculated to 
quantify the effect of an sgRNA on cell growth in the presence of imatinib. Specifically, τ 
values were calculated as:
τx = log2
Nt
x
Nt0
x
Nt
NTC
Nt0
NTC
where Nx denotes the frequency of sgRNA x and NNTC denotes the frequency of non-
targeting control sgRNAs at baseline (t0) or after imatinib treatment (t). Gene-level 
phenotypes were calculated by averaging the phenotypes of the top 25% most extreme 
sgRNAs targeting this gene. The statistical significance for each gene is determined by 
comparing the set of τ values for sgRNAs targeting it with the set of τ values for non-
targeting control sgRNAs using the Mann-Whitney U test, as described previously44. To 
correct for multiple hypothesis testing, we first performed random sampling with 
replacement among the set of τ values for non-targeting control sgRNAs and calculated p 
values for each sampling. Then, we calculated the false discover rate (FDR) based on the 
distribution of P values for all genes in the library and for non-targeting controls generated 
above. The P-value cutoff was chosen based on an FDR < 0.05.
For the orthogonal double-sgRNA screen, combinations of non-targeting control sgRNAs 
served as negative control, combinations of one non-targeting control sgRNA and one 
targeted sgRNA were used to determine single-sgRNA phenotypes and combinations of two 
targeted sgRNAs were used to calculate double phenotypes. Raw read counts used for 
analysis are shown in Supplemental Table 10. We then implemented a series of filtering 
steps on the sgRNA level. First of all, on the SaCas9 nuclease side, p values were calculated 
for each gene as described above. Only the sgRNAs targeting genes that have significant 
editing phenotypes (P value < cutoff) were retained. Subsequently, GI scores were calculated 
using the ‘force-fit’ definition for genetic interactions on the sgRNA level and sgRNAs were 
further filtered by GI correlation as described previously 44. On the CRISPRa side, if two 
sgRNAs targeting the same gene have low correlation, the gene was excluded for further 
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analysis. After the filtering process, gene-level phenotypes and GI scores were calculated by 
averaging all double-sgRNAs targeting the same gene-gene combinations.
Directional genetic interaction network model
Genetic interactions whose GI scores exceeded a 1x standard deviation consistently in both 
clonal screen replicates were used to construct a GI network (Supplemental Table 7). To 
quantify directionality in these reproducible genetic interactions, a directionality score (Ψ) 
was calculated as
ψ = τactivation × τknockout × GI
2
resulting in a negative Ψ when gene activation and knockout had opposing phenotypes. 
Negative Ψ values below a negative 1x standard deviation of all calculated Ψ values were 
used to infer the direction of genetic interactions. The network analysis software platform 
Cytoscape50 was used to visualise the genetic interaction model. Where applicable, 
directionality in GIs was indicated by arrow shaped edges and line shaped edges indicate 
significant GIs for which directionality could not be inferred. Nodes were coloured 
according to gene function with blue symbolizing genes that act to decrease and red to 
increase cell fitness of imatinib treated cells.
Arrayed competitive growth validation experiments
Individual CRISPRa or orthogonal dual sgRNA sequences for validation experiments were 
sub-cloned into the same vector as the respective libraries. For that purpose oligonucleotides 
encoding the sgRNA sequence as well as the reverse complementary sgRNA sequence were 
synthesised with compatible 4 nucleotide 5′-overhangs for cloning into the SpCas9 (top 
strand: TTGG, bottom strand: AAAC) or SaCas9 (top strand: GCTG, bottom strand: AAAC) 
position of the target vector respectively (for vector preparation see above). Oligonucleotides 
were adjusted to 100 uM and reverse complementary strands were mixed, heated to 99°C 
and cooled down to 4°C at a ramp rate of −0.1°C/sec in a thermocycler. Annealed 
oligonucleotide double strands were diluted 1:200 and 1 uL was mixed with 50 ng digested 
vector, 1 uL 10x T4 ligase buffer (NEB) and 0.5 uL T4 ligase (2000U/uL, NEB) in a total 
volume of 10 uL. Following incubation for 30 min at room temperature, 1 uL ligation 
reaction was transformed into 20 uL chemically competent DH5α E.coli, plated on LB-amp 
(100 ug/mL) agar plates and incubated at 37°C overnight. Individual clones were picked and 
sgRNA sequences were validated via Sanger sequencing.
All library vectors co-expressed mCherry which was used to track the abundance of sgRNA 
expressing cell populations in growth competition assays. For this purpose, sgRNA 
expressing cells were mixed with parental - mCherry-negative – cells at ratios between 1:1 
and 1:3 in 96-well plates before repeated treatment with imatinib, R428 or no drug for 
indicated time periods. Enrichment or depletion of the mCherry positive (sgRNA 
expressing) cell population, indicating an increase or decrease of fitness over time following 
sgRNA expression and could conveniently be followed via FACS quantification of the 
mCherry-positive (sgRNA expressing) versus mCherry negative (parental, no sgRNA 
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expressing) population. For screen validation experiments, τ values for each sgRNA were 
calculated equivalent to screen τ values:
τx = log2
Nt
x
Nt0
x
Nt
NTC
Nt0
NTC
where N represents the fraction of sgRNA expressing (mCherry-positive/mCherry-negative) 
baseline cells (t0) or indicated time points (t) and X represents a given sgRNA while NTC 
represents a scrambled non-target control sgRNA. Each value was quantified from three 
technical replicates. Where indicated, fold-enrichment or fold-change values were calculated 
as 2 to the power of τ (2τ). The sgRNA sequences used for validation of candidate genes 
from the primary CRISPRa screen are shown in Supplemental Table 3.
For validation of genetic interactions, dual sgRNA expression constructs were cloned into 
sgLenti-orthogonal using CRISPRa sgRNAs for SPRED2 (5′-
GATTCGGAGCCAGACGGTCG-3′), WT1 (5′-GGACTCACTGCTTACCTGAA-3′), 
TFAP2A (5′-AGGGGAATGTGGCGGAATTG-3′) and non-target control (5′-
CCCTGCCGTCCTCTACGAAT-3′) and SaCas9 nuclease sgRNAs for NF1 (5′-
TTGTCTTTGGGTGTATTAGCAA-3′), MAP4K5 (5′-
AGCAGGACTACGAACTCGTCCA-3′), PTPN1 (5′-
ACTTTCTTGATATCAACGGAAG-3′), RASA2 (5′-
CCCACTAGAGAAACTGTTGCAT-3′) and non-target control (5′-
ACGCGTGCGTAATGAGAGGATC-3′). Combinatorial sgRNA expression vectors were 
transduced into the orthogonal clonal line 2 used in the orthogonal screen. For arrayed 
validation experiments, genetic interaction scores (GIv) were calculated as:
GIv = (τactivation + knockout) − (τactivation + τknockout)
Ψ scores from arrayed validation data (Ψv) were calculated as:
ψv = τactivation × τknockout × GIv
2
Cell viability assays
Cells were seeded at 10,000 cells per 96-well in 200 uL RPMI-1640 (10% FBS, 1% Anti-
Anti) with indicated imatinib and/or R428 concentrations. Viability was determined at 
indicated time points by mixing 100 uL cell suspension with 50 uL resazurine medium (50 
ug/mL, Acros Organics). After 2h incubation, fluorescence was quantified on a plate reader 
(BMG Labtech) at excitation: 530 nm and emmision: 590 nm.
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RNAseq
RNA from K562 CRISPRa cells was extracted using RNeasy Mini kit (Qiagen). Sequencing 
libraries were prepared using the TruSeq mRNA stranded kit (Illumina) and sequenced via 
SE 50bp RNAseq on a HiSeq2000 platform. Reads were aligned to Homo sapiens Ensembl 
GRCm38v.78 using STAR_2.4.2a.
Quantitative RT-PCR
Total RNA from sgRNA expressing cells was purified using Rneasy Mini columns (Qiagen). 
Taqman probe assays (Applied Biosystems) were used with FAM labelled probes for target 
genes and VIC labelled probes for the housekeeping gene HPRT1. Reactions were carried 
out using the one step qRT-PCR master mix TaqMan RNA-to-CT (Applied Biosystems) 
according to the manufacturer’s instructions on the 2900 HT Fast RT-PCR machine (Applied 
Biosystems).
Western blot analyses
NF1-Null HEK293T cells were generated using SpCas9 and sgRNA targeting exon 2 with 
the sequence 5′-AGTCAGTACTGAGCACAACA-3′ (Shalem, O., et al., 2013). Following 
single cell cloning, target sequence amplification by PCR, TOPO cloning, and Sanger 
sequencing, both NF-1 alleles were confirmed deleted by a 1bp insertion resulting in 
NF1(N39fs) and a 11bp deletion resulting in NF1(S35fs). HEK293T cells were transfected 
with pcDNA3.1 Flag-eGFP (CTRL) and Flag-SPRED2 (SPRED2) using Lipofectamine 
2000 (ThermoFisher Scientific, 11668019), serum starved for 24 hours, and stimulated with 
20ng/ml recombinant human EGF (Invitrogen, PHG0311). Cells were washed with PBS and 
lysed in TNM buffer (0.2 M Tris pH 7.5, 1% Triton X-100, 1.5M NaCl, 50 mM MgCl2, 
1mM DTT, protease and phosphatase inhibitor cocktails. Lysate was cleared and 1,000ug 
protein was subject GST-Raf1 RBD agarose beads (McCormick lab, in house) for 1.5 hours. 
Samples were analysed by Western blot using the following antibodies: NF1 (SCBT, sc-67 
[D]), Flag (Sigma, F1804), pan-Ras (Cytoskeleton, Inc, AESA02), β-Actin (Sigma, A5441).
K562 orthogonal cells were transduced with lentivirus expressing S.aureus sgRNAs: sgNTC 
5′-ACGCGTGCGTAATGAGAGGATC-3′ (NF1-wildtype) or sgNF1 5′-
TTGTCTTTGGGTGTATTAGCAA-3′ (NF1-knockout). At 2 days post transduction, NF1-
wildtype and -knockout cells were selected with puromycin (2 ug/mL) for 5 days and 
recovered for 2 additional days before treatment with vehicle (DMSO), 300nM imatinib, 
1μM R428, or imatinib + R428 for 48hrs. Whole cell lysates were collected by lysis in RIPA 
buffer (150 mM NaCl, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM 
Tris pH 8.0) and lysate concentration determined by BCA assay (ThermoFisher). 20 μg of 
lysate corresponding to each sample was separated by SDS-PAGE and transferred to a 
PVDF membrane by wet transfer (250mA, 2hrs). Western blot analysis was carried out 
following standard conditions using p-AXL antibody (R&D Technologies; Y779), followed 
by re-probing with β-actin antibody (Sigma; AC-74) to confirm equal loading.
Time-resolved fluorescence resonance energy transfer (TR-FRET) assay
TR-FRET assay utilizing the terbium/Venus as energy donor/acceptor was performed as 
described previously35. Briefly, HEK293T cells were transfected with GST- and Venus-
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tagged genes. Cells were lysed in FRET buffer (20 mM Tris, pH 7.0, 0.01% Nonidet-P40, 
and 50 mM NaCl with proteinase and phosphatase inhibitors) followed by three freeze-and-
thaw cycles. Terbium conjugated Anti-GST antibody (Cisbio Bioassays, Codolet, France) 
was 1:1000 diluted in FRET buffer and dispensed into each well with MultidropTM Combi 
Reagent Dispenser (ThermoScientific). The lysate-antibody mixtures were incubated at 4°C 
before the TR-FRET signal was recorded (EnVision reader setting: Ex 337 nm, Em1: 520 
nm, Em2: 486 nm; mirror: D400/D505 dual; time delay: 50 μs). The TR-FRET signal is 
expressed as the FRET ratio (F520/F486 × 104).
Data availability
Sequencing data from the CRISPRa screen and RNAseq are available at Sequence Read 
Archive accession number SRP127017 under BioProject ID PRJNA422995. All relevant 
additional data has been published with the manuscript, either as part of the main text or in 
the supplement. Plasmids and their sequences are deposited at Addgene.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Ultra-complex CRISPRa screen identifies hundreds of genes involved in cancer 
signalling pathways
a, Schematic of genome-scale CRISPRa screening approach (see text for details). b, 
Overview of CRISPRa screen results. Negative τ values indicate depletion and positive 
values enrichment of cells following imatinib selection. Significant candidate genes 
(FDR<0.05, p<0.001) are in colour (blue = depleted, red = enriched). Validated candidate 
genes are labelled in black. Mann-Whitney U test was used to calculate p-values as 
described previously44. To correct for multiple hypothesis testing, we first performed 
random sampling with replacement among the set of τ values for non-targeting control 
sgRNAs and calculated p-values for each sampling. Then, we calculated the false discover 
rate (FDR) based on the distribution of p-values for all genes in the library and for non-
targeting controls generated above. c, Candidate gene validation. Enrichment of candidate 
sgRNA expressing cells was measured over time. Values represent the mean of three 
different sgRNAs targeting each gene with s.e.m. Grey shading = two standard deviations of 
sgNTCs at day 15. All values from separate sgRNAs on days 7, 11 and 15 normalised to 
baseline or untreated cells are shown in Supplemental Table 3.
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Figure 2. The orthogonal CRISPR system
a, Schematic of the orthogonal system on the example of imatinib efflux transporter 
ABCG2. Combination of CRISPR systems from S.pyogenes (CRISPRa) and S.aureus (Cas9 
nuclease) allows the simultaneous activation and knockout of genes in the same cell simply 
by expressing two appropriate sgRNAs. b, Orthogonal system is able to modulate ABCG2 
protein levels. Flow cytometry analysis of ABCG2 levels following CRISPRa mediated 
activation of ABCG2 without (left) or with (right) SaCas9 nuclease mediated knockout of 
ABCG2 (grey histogram = sgNTC for both CRISPR systems). A representative result from 
n>10 independent experiments with similar results is shown. c, Orthogonal system can 
control imatinib response. Enrichment of imatinib treated cells with activated ABCG2 
with/out SaCas9 nuclease mediated knockout of ABCG2. Values represent the mean of 
independent experiments (n=3) with s.e.m. and statistical significance was determined via 
two-tailed, homoscedastic t-test with * = p<0.05, ** =p<0.01 and *** = p<0.001.
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Figure 3. Orthogonal CRISPR screens can quantify directional genetic interactions
a, Concept of the application of the orthogonal system for directional gene interaction 
studies. In the same cell, one gene is activated (CRISPRa) while another gene in knocked 
out (SaCas9 nuclease). b–d, Correlation of τ values from two clonal cell line replicates is 
shown for b, gene activation, c, gene knockout and d, all possible combinations thereof. 
Correlation values (r) are Pearson product-moment correlation coefficients. e, Schematic of 
perturbation data set from each gene pair (blue = depleted, red = enriched, NTC = non-target 
control sgRNA) f, Formula for calculating Ψ scores. Negative Ψ scores define interactions 
in which directionality could be inferred. g, To determine which of both interaction partners 
acts up- or downstream, τactivation values were multiplied with genetic interaction scores. 
Positive values indicate a downstream function, negative values an upstream function of the 
activated gene. h, Based on GI and Ψ scores determined by the full orthogonal interaction 
screen, a genetic interaction model was constructed. For positive regulators of cell fitness, 
nodes are shown in red and negative regulators in blue. Arrow-shaped edges indicate 
inferred directional interactions between nodes. Line-shaped edges symbolise genetic 
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interactions where directionality could not be inferred. Node sizes are proportional to the 
degree of connectivity. In total, 2258 gene:gene combinations that passed the filter criteria 
were considered for the construction of the directional genetic interaction network.
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Figure 4. Validation of a directional Ras-centric genetic sub-network
a, Relative fitness (τ) was measured over 14 days following gene activation, knockout or the 
combination of both. From those values, genetic interaction (GIv) as well as directionality 
(Ψv) scores were calculated. NTC = non-target control sgRNA. b, Twelve activation/
knockout combinations were re-tested in an arrayed format from which ten were predicted 
by the orthogonal screen to show a directional genetic interaction. Eight combinations 
displayed the same trend of directional interactions predicted by the orthogonal screen data 
while two interactions did not reproduce (see also Supplemental Table 9). Single 
perturbation, and combinatorial τ values are shown following 14 days of imatinib selection 
(mean with s.e.m. from technical replicates (n=3)) along with calculated GIv and Ψv scores 
for each gene:gene combination. c, A directional genetic interaction model was assembled 
based on validated interactions from b. Arrows indicate the direction of the functional 
dependencies as explained in the text but do not suggest direct physical interactions. Values 
represent Ψv scores calculated from τ values in b. Each directional interaction was 
reproduced three times independently.
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Figure 5. Exploiting genetic dependencies for cancer therapy
a, NF1-knockout K562 cells are significantly more sensitive to the AXL kinase inhibitor 
R428 than NF1-wildtype cells. Cells were treated for 8 days with 500 nM R428 on day 0 
and day 4. (mean with s.e.m. from technical replicates (n=6)). b, NF1-knockout K562 cells 
are significantly more resistant to imatinib but can be re-sensitised by R428 treatment (mean 
with s.e.m. from technical replicates (n=4 for imatinib and n=2 for imatinib + R428 treated 
cells). In panel a and b, statistical significance was determined via two-tailed, 
homoscedastic t-test with * = p<0.05, **=p<0.01 and *** = p<0.001. c, NF1-knockout cells 
accumulate elevated levels of phosphorylated AXL kinase (p-AXL) which can be reduced 
by treatment with the AXL kinase inhibitor R428. Quantification of the ratio of band 
intensity from p-AXL/β-actin, normalised to p-AXL levels in NF1-wt untreated cells is 
shown. The experiment was performed once. d, TR-FRET assay shows direct interaction 
between NF1 and AXL in HEK293T cells. Shown is the mean with s.d. from three 
independent experiments.
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